| Home  | About ScienceAsia  | Publication charge  | Advertise with us  | Subscription for printed version  | Contact us  
Editorial Board
Journal Policy
Instructions for Authors
Online submission
Author Login
Reviewer Login
Volume 48 Number 6
Volume 48 Number 5
Volume 48 Number 4
Volume 48 Number 3
Volume 48 Number 2
Volume 48S Number 1
Earlier issues
Volume 42 Number 2 Volume 42 Number 3 Volume 42 Number 4

previous article next article

Research articles

ScienceAsia 42 (2016): 201-206 |doi: 10.2306/scienceasia1513-1874.2016.42.201

Long non-coding RNA PCGEM1 as a biomarker for prostate cancer

Wei Yanga, Fawei Hea, Yuan Lia, Yangkui Zhaib, Bo Tana, Haixiang Wua,*

ABSTRACT:     Prostate cancer (PC) is the second most common diagnosed malignant disease. Long non-coding RNAs (lncRNAs), which account for approximately 98% of the human genome, are becoming increasingly interesting with regard to various diseases and have great potential for diagnosis and prognostic monitoring of PC. To identify a new diagnosis marker for metastatic PC, we enrolled a total of 144 patients with PC, including 57 metastatic and 87 localized PC patients, and 148 healthy subjects. Patients were followed up routinely at 3-month intervals for 5 years. The expression of 10 selected lncRNAs in peripheral blood from participants was measured. Among the 10 selected lncRNAs, the expression of PCGEM1 in the metastatic group was 2.57 times that in the localized group (p<0.001) and 2.96 times that in the control group (p<0.001). Patients with higher AJCC stage had significantly elevated PCGEM1 expression (one-way ANOVA, p<0.001). The relative expression of PCGEM1 in patients with higher Gleason score was also higher than that in patients with lower Gleason score (p=0.003). Moreover, patients with more than 5 years survival time had significantly lower PCGEM1 expression than the rest (p=0.017) and patients with elevated PCGEM1 relative expression had significantly shorter survival time (p<0.001). The present study suggested that PCGEM1 expression in peripheral blood could act as a diagnostic marker of metastatic PC. It would also be a prognostic marker to predict the survival time.

Download PDF

10 Downloads 1225 Views

a Department of Ultrasonics, Sichuan Provincial Cancer Hospital, 610041, Sichuan, China
b Metabolic Disease Hospital, Tianjin Medical University, 300070, Tianjian, China

* Corresponding author, E-mail: HXW_1971@163.com

Received 21 Apr 2015, Accepted 0 0000